What are the recommendations for the treatment of hyperlipidemia in stage C HF?
The recommendations for the treatment of hyperlipidemia in Stage C HF include PUFA supplementation as reasonable to use as adjunctive therapy in patients with NYHA class II to IV symptoms and HFrEF or HFpEF, unless contraindicated, to reduce mortality and cardiovascular hospitalizations. Statins are not beneficial as adjunctive therapy when prescribed solely for the diagnosis of HF in the absence of other indications, and routine use of statins for the treatment of HF is not indicated outside of current practice guidelines for the primary and secondary prevention of atherosclerotic vascular disease.